Floatz logo

Bendamustine

Recurrent Female Reproductive System Carcinoma

Mayo ClinicSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

51 Active assets in the Recurrent Female Reproductive System Carcinoma cohort.

Asset / SponsorPhaseRating
Inno-206
AstraZeneca
Phase 2BB
Carboplatin
AbbVie
Phase 2/3BB
Indocyanine Green
Istanbul University
Phase 4BB
Ipilimumab
M.D. Anderson Cancer Center
Phase 2B
Atezolizumab
M.D. Anderson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Bendamustine is also rated in:

mantle cell lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →